Overview

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Status:
Terminated

Trial end date:
2014-10-23

Target enrollment:

Participant gender:

Summary

This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Tamoxifen